Navigation Links
Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
Date:7/17/2014

WASHINGTON, July 17, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the second quarter of 2014 on Thursday, August 7, 2014, before the market opens.

The Company will host a conference call at 10:00 AM ET on Thursday, August 7, 2014, during which Vanda management will discuss the second quarter 2014 financial results and other corporate activities. To participate in the conference call, please dial 1-800-708-4540 (domestic) or 1-847-619-6397 (international) and use passcode 37729521.

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com.  Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, August 7, 2014, beginning at 12:30 PM ET and will be accessible until Thursday, August 14, 2014, at 11:59 PM ET.  The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers.  The passcode number is 37729521.

ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Investor Contact:
Jim Kelly
Senior Vice President & Chief Financial Officer
Vanda Pharmaceuticals, Inc.
(202) 734-3428
jim.kelly@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
2. Vanda Pharmaceuticals Reports First Quarter 2013 Results
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
5. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
6. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
7. Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
8. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
9. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
10. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
11. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... a leading digital health company, and Digital ... telemedicine and remote patient monitoring, announce they are ... DN Telehealth maximizes collaboration compatibility ... extending consultations beyond a physical clinical setting to ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... The ... announce a new partnership with Compass Research . GGI's mission is to advance ... vaccine to a child in need in honor of each clinical trial volunteer. The ...
Breaking Biology Technology:
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
(Date:1/19/2017)... , January 19, 2017 According to a new report ... Forecast, 2014 - 2022," the global biometric sensor market is expected to garner ... 2022. In 2015, Asia-Pacific dominated the global market and ... sectors. Continue Reading ... ...
Breaking Biology News(10 mins):